Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Monopar Therapeutics Inc. (MNPR : NSDQ)

• Company Description    Monopar Therapeutics Inc. is a biopharmaceutical company. It is focused on developing drugs for cancer patients. The company's intellectual property pipeline consists of Validive(R), Camsirubicin (MNPR-201) and MNPR-101 which are in clinical stage. Monopar Therapeutics Inc. is based in Wilmette, United States. Number of Employees: 10

• Price / Volume Information    Yesterday's Closing Price: $1.97 Daily Weekly Monthly 20 Day Moving Average: 12,643 shares Shares Outstanding: 12.62 (millions) Market Capitalization: $24.86 (millions) Beta: 0.77 52 Week High: $6.98 52 Week Low: $1.70 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -17.10% -9.17% 12 Week -36.45% -31.05% Year To Date -38.63% -27.02%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 1000 SKOKIE BLVD SUITE 350 - WILMETTE,IL 60091 USA ph: 847-388-0349 fax: - info@monopartx.com http://www.monopartx.com

• General Corporate Information    Officers Chandler Robinson - Chief Executive Officer Christopher Starr - Executive Chairman Kim Tsuchimoto - Chief Financial Officer Raymond W. Anderson - Director Michael Brown - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 61023L108 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/22 Next Expected EPS Date: 08/11/22 Share - Related Items Shares Outstanding: 12.62 Most Recent Split Date: (:1) Beta: 0.77 Market Capitalization: $24.86 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.24 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.91 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/11/22

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.47 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -18.75% vs. Previous Quarter: 9.52% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 03/31/22 - -48.28 12/31/21 - -41.07 09/30/21 - -39.90 ROA 03/31/22 - -45.44 12/31/21 - -38.99 09/30/21 - -37.98 Current Ratio 03/31/22 - 16.77 12/31/21 - 12.98 09/30/21 - 18.10 Quick Ratio 03/31/22 - 16.77 12/31/21 - 12.98 09/30/21 - 18.10 Operating Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Net Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Pre-Tax Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Book Value 03/31/22 - 1.34 12/31/21 - 1.50 09/30/21 - 1.69 Inventory Turnover 03/31/22 - - 12/31/21 - - 09/30/21 - - Debt-to-Equity 03/31/22 - 0.00 12/31/21 - 0.00 09/30/21 - 0.00 Debt-to-Capital 03/31/22 - 0.00 12/31/21 - 0.00 09/30/21 - 0.00

Powered by Zacks Investment Research ©